Serum Free Light Chain Ratio, Total κ/λ Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

被引:29
作者
Giarin, Manuela M. [1 ]
Giaccone, Luisa [1 ]
Sorasio, Roberto [1 ]
Sfiligoi, Christian [1 ]
Amoroso, Barbara [2 ]
Cavallo, Federica [1 ]
Cipriani, Alessia [1 ]
Palumbo, Antonio [1 ]
Boccadoro, Mario [1 ]
机构
[1] Azienda Osped San Giovanni Battista Torino, Div Ematol Univ, I-10126 Turin, Italy
[2] Binding Site, Rome, Italy
关键词
INDEPENDENT RISK-FACTOR; PROGRESSION; THERAPY; AMYLOIDOSIS; MARKER; TIME;
D O I
10.1373/clinchem.2009.124370
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: The prognostic value of changes in paraprotein markers after stem cell transplantation is unknown. We evaluated disease response using serum immunofixation (s-IFIX), total kappa and lambda ratio (KLR), and free light chain (FLC) ratio in myeloma patients who underwent autologous or autologous plus allogeneic stem cell transplantation. METHODS: We studied s-IFIX, KLR, and FLC ratio in sera from 203 patients, 3 months after transplantation. We evaluated overall and event-free survival (OS and EFS, interval between date of study enrollment and date of death from any cause or date of progression, relapse, or death from any cause, respectively) by the Kaplan-Meier method. RESULTS: Of the 203 patients, 51 were negative by s-IFIX, 99 reached a normal KLR, and 92 had a normal FLC ratio. Of the 51 patients with negative s-IFIX, 40 (78%) also had a normal FLC ratio. The median duration of OS was 54.3 months, and the median EFS was 19.5 months. None of the measured paraprotein parameters showed an association with OS. Only a normal KLR was associated with prolonged EFS (P = 0.016). Even a negative s-IFIX associated with a normal FLC ratio did not show a significant difference in terms of EFS and OS. CONCLUSIONS: Our analysis with a small cohort of patients did not show a significant impact of achieving complete response (CR) or stringent CR on patient survival. (C) 2009 American Association for Clinical Chemistry
引用
收藏
页码:1510 / 1516
页数:7
相关论文
共 35 条
  • [1] Quantitative analysis of serum free light chains - A new marker for the diagnostic evaluation of primary systemic amyloidosis
    Abraham, RS
    Katzmann, JA
    Clark, RJ
    Bradwell, AR
    Kyle, RA
    Gertz, MA
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (02) : 274 - 278
  • [2] AGUZZI F, 1991, Giornale Italiano di Chimica Clinica, V16, P323
  • [3] Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: Correlation with 24-hr urinary light-chain excretion
    Alyanakian, MA
    Abbas, A
    Delarue, R
    Arnulf, B
    Aucouturier, P
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2004, 75 (04) : 246 - 248
  • [4] ATTAL M, 2003, NEW ENGL J MED, V349, P26
  • [5] Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x
  • [6] Serum free light chain measurements move to center stage
    Bradwell, AR
    [J]. CLINICAL CHEMISTRY, 2005, 51 (05) : 805 - 807
  • [7] Bradwell AR, 2001, CLIN CHEM, V47, P673
  • [8] Serum test for assessment of patients with Bence Jones myeloma
    Bradwell, AR
    Carr-Smith, HD
    Mead, GP
    Harvey, TC
    Drayson, MT
    [J]. LANCET, 2003, 361 (9356) : 489 - 491
  • [9] BRADWELL AR, 2005, SERUM FREE LIGHT CHA, P237
  • [10] A comparison of allografting with autografting for newly diagnosed myeloma
    Bruno, Benedetto
    Rotta, Marcello
    Patriarca, Francesca
    Mordini, Nicola
    Allione, Bernardino
    Carnevale-Schianca, Fabrizio
    Giaccone, Luisa
    Sorasio, Roberto
    Omede, Paola
    Baldi, Ileana
    Bringhen, Sara
    Massaia, Massimo
    Aglietta, Massimo
    Levis, Alessandro
    Gallamini, Andrea
    Fanin, Renato
    Palumbo, Antonio
    Storb, Rainer
    Ciccone, Giovannino
    Boccadoro, Mario
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (11) : 1110 - 1120